drugset / Trial / NCT00345904

Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above

NCT00345904

Phase 3 Completed 120 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

Vaccination is currently the most effective mean of controlling influenza and preventing its complications and mortality in persons at risk. Because of the variable nature of influenza viruses, the composition of influenza vaccines changes almost every year, to target the 3 main circulating strains. Each year the influenza vaccine formulation may thus be different and clinical studies are mandated to ensure that the immunogenicity and safety of the vaccine formulated from the three annual circulating strains are similar to what was observed during the previous years. This study is designed to test the immunogenicity and reactogenicity of the Fluarix™ vaccine containing the influenza strains recommended for the 2006-2007 season.

Timeline

Start
2006-07
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza Virus Vaccine Vaccine

Indications